THOMAS SCHLEPKO: Open Payments
NPI 1659519866 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$699 in 31 payments from 8 companies in 2025. Trend: 2023 $646 · 2024 $521 · 2025 $699
Food & beverage: $699
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 13 | $288 |
| Gilead Sciences, Inc. | 8 | $168 |
| Merck Sharp & Dohme LLC | 3 | $79 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $53 |
| E.R. Squibb & Sons, L.L.C. | 2 | $48 |
| ABBVIE INC. | 1 | $23 |
| EMD Serono, Inc. | 1 | $21 |
| GlaxoSmithKline, LLC. | 1 | $19 |
Products named: APRETUDE, DOVATO, PIFELTRO, Biktarvy, CABENUVA, CAPLYTA, COBENFY, RUKOBIA.
Industry payments across FL — which companies pay providers there.
